Retinal Vasculitis After Administration of Brolucizumab Resulting in Severe Loss of Visual Acuity-Reference-Cited by-同舟云学术

Retinal Vasculitis After Administration of Brolucizumab Resulting in Severe Loss of Visual Acuity

Published:2020-10-01 Issue:10 Volume:138 Page:1103
ISSN:2168-6165
Container-title:JAMA Ophthalmology
language:en
Short-container-title:JAMA Ophthalmol

Author:

Kondapalli Srinivas Sai A.¹

Affiliation:

1. Everett and Hurite Ophthalmic Association, Pittsburgh, Pennsylvania

Publisher

American Medical Association (AMA)

Subject

Ophthalmology

Link

https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2768911/jamaophthalmology_kondapalli_2020_lo_200007_1601757521.38293.pdf

Reference1 articles.

1. Center for Drug Evaluation and Research. Application number: 761125Orig1s000 summary review. Published October 10, 2017. Accessed April 7, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761125Orig1s000SumR.pdf

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on Retinal Drug Safety: Proceedings of the ASRS ReST Committee Webinar Part 1;Journal of VitreoRetinal Diseases;2024-08-22

2. Retreatment with faricimab in prior brolucizumab-related intraocular inflammation eyes;Taiwan Journal of Ophthalmology;2024-04-26

3. Visual outcomes of intraocular inflammation after brolucizumab injection in Japanese patients with neovascular age-related macular degeneration;PLOS ONE;2024-04-18

4. Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review;Journal of Clinical Medicine;2023-07-14

5. RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION;Retina;2023-06-16